Jim Simons Adaptimmune Therapeutics PLC Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,656,575 shares of ADAP stock, worth $993,945. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,656,575

Previous 1,786,341 7.26%

Holding current value

$993,945

Previous $1.75 Million 10.11%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.92 - $1.39 $119,384 - $180,374	-129,766 Reduced 7.26%	1,656,575 $1.57 Million
Q2 2024 Aug 09, 2024	BUY	$0.83 - $1.47 $327,489 - $580,012	394,566 Added 28.35%	1,786,341 $1.75 Million
Q1 2024 May 13, 2024	BUY	$0.7 - $1.75 $15,075 - $37,688	21,536 Added 1.57%	1,391,775 $2.2 Million
Q4 2023 Feb 13, 2024	BUY	$0.43 - $0.79 $147,222 - $270,479	342,379 Added 33.31%	1,370,239 $1.09 Million
Q3 2023 Nov 14, 2023	SELL	$0.73 - $1.04 $349,315 - $497,655	-478,515 Reduced 31.77%	1,027,860 $802,000
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $1.19 Million - $2 Million	1,323,675 Added 724.51%	1,506,375 $1.39 Million
Q1 2023 May 12, 2023	SELL	$1.06 - $2.16 $400,969 - $817,069	-378,273 Reduced 67.43%	182,700 $199,000
Q4 2022 Feb 13, 2023	SELL	$1.05 - $2.53 $5,521 - $13,305	-5,259 Reduced 0.93%	560,973 $819,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $59,605 - $135,519	56,232 Added 11.03%	566,232 $609,000
Q2 2022 Aug 12, 2022	SELL	$1.33 - $2.28 $598,104 - $1.03 Million	-449,703 Reduced 46.86%	510,000 $867,000
Q1 2022 May 13, 2022	BUY	$1.73 - $4.06 $920,387 - $2.16 Million	532,016 Added 124.39%	959,703 $1.98 Million
Q4 2021 Feb 11, 2022	BUY	$3.5 - $5.68 $1.5 Million - $2.43 Million	427,687 New	427,687 $1.6 Million
Q3 2021 Nov 12, 2021	SELL	$3.44 - $6.37 $1.04 Million - $1.93 Million	-303,495 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.86 - $5.78 $781,630 - $1.17 Million	202,495 Added 200.49%	303,495 $1.29 Million
Q1 2021 May 13, 2021	SELL	$4.9 - $6.83 $3.88 Million - $5.4 Million	-791,095 Reduced 88.68%	101,000 $536,000
Q4 2020 Feb 10, 2021	SELL	$4.0 - $9.2 $1.72 Million - $3.95 Million	-429,516 Reduced 32.5%	892,095 $4.81 Million
Q3 2020 Nov 13, 2020	SELL	$7.66 - $10.78 $2.94 Million - $4.14 Million	-383,800 Reduced 22.5%	1,321,611 $10.5 Million
Q2 2020 Aug 13, 2020	SELL	$2.58 - $12.1 $114,936 - $539,042	-44,549 Reduced 2.55%	1,705,411 $17.1 Million
Q1 2020 May 14, 2020	BUY	$1.2 - $4.52 $341,780 - $1.29 Million	284,817 Added 19.44%	1,749,960 $4.76 Million
Q4 2019 Feb 13, 2020	BUY	$0.72 - $1.43 $422,196 - $838,529	586,384 Added 66.73%	1,465,143 $1.76 Million
Q3 2019 Nov 13, 2019	BUY	$1.43 - $3.81 $545,772 - $1.45 Million	381,659 Added 76.78%	878,759 $1.33 Million
Q2 2019 Aug 12, 2019	SELL	$3.23 - $5.41 $960,602 - $1.61 Million	-297,400 Reduced 37.43%	497,100 $2 Million
Q1 2019 May 14, 2019	BUY	$3.63 - $6.06 $610,566 - $1.02 Million	168,200 Added 26.86%	794,500 $3.42 Million
Q4 2018 Feb 13, 2019	BUY	$3.76 - $14.16 $2.35 Million - $8.87 Million	626,300 New	626,300 $3.6 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account